Detalles de la búsqueda
1.
p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.
Mod Pathol
; 36(4): 100100, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36788081
2.
Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions.
Curr Oncol Rep
; 25(5): 491-500, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36862337
3.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 625-635, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405088
4.
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Breast Cancer Res
; 24(1): 58, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36056374
5.
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
Mod Pathol
; 35(12): 1804-1811, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35842479
6.
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
Breast Cancer Res
; 23(1): 36, 2021 03 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33736679
7.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Int J Cancer
; 148(10): 2614-2627, 2021 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533487
8.
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Breast Cancer Res
; 22(1): 47, 2020 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32408905
9.
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Cancer
; 126(22): 4847-4858, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32780421
10.
Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers.
Arch Gynecol Obstet
; 289(3): 663-70, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24045978
11.
Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
Oncology
; 85(2): 69-77, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23860180
12.
A retrospective investigation of women's experience with breast reconstruction after mastectomy.
Arch Gynecol Obstet
; 287(3): 555-61, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23090185
13.
HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation.
Breast Care (Basel)
; 18(6): 455-463, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38125917
14.
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
JAMA Oncol
; 9(7): 946-954, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37166817
15.
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
J Clin Oncol
; 41(22): 3796-3804, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36809046
16.
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Clin Cancer Res
; 29(4): 805-814, 2023 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36441798
17.
The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.
Breast Cancer Res
; 14(6): R156, 2012 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-23216834
18.
A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity.
Breast Cancer Res Treat
; 135(1): 167-75, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22729890
19.
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Clin Cancer Res
; 28(22): 4995-5003, 2022 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35797219
20.
Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma.
J Pathol Clin Res
; 8(2): 191-205, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34889530